Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by anglography  by Chatteriee, Tushar et al.
5 
--_= 
r~ 
~5 
o 
204A 
via Smad3- and Smad4-depandent pathways in synergy with bHLH transcription factors 
such as TFE3. However, deepita the presence of two Smad-binding elements and an E- 
box at the 4G / 5G polymorphism in the PAl-1 promoter, this region does not appear to be 
a major contributor to TGF-J] induction of PAl-1 promoter activity. Taken together, these 
data indicate that TGF-~ is unlikely to be an allele-selective regulator of PAl-1 gene 
expression, 
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1007MP-130 Thrombin Activatable Flbrlnolyais Inhibitor (TAFI) 
Levels in Patients With Coronary Artery Disease 
Investigated by Anglography 
Tushar Oh~atteriee, Verena Schroeder, Martin Fleisch, Stefan Windecker, Christian Seller, 
Franz R. Ebadi, Bernhard Meier, Hans P, Kohler, Swiss Cardiovascular Center Bern, 
University Hospital, Inselspital, Bem, Switzerland, Laboratory for Thrombosis Research, 
University Hospital, Inselspital, Bern, Switzerland. 
Background: Thrombin activatable fibrinolysis inhibitor (TAFI), also known as plasma 
procarboxypeptidase B or carboxypeptidase U, is a recently described component which 
is involved in the regulation of the balance between coagulation and fibrinolysis. When 
activated by the thrombin-thrombomodulin complex, TAFI leads to a potent inhibition of 
tPA-inducad fibrinolysis. High TAFI antigen plasma levels may therefore contribute to an 
increased dsk for thrombotic disorders. There are no data available about TAFI antigen 
levels in patients with coronary artery disease (CAD) and subjects free of CAD both 
investigated by angiography. 
Material and Methods: 123 subjects admitted for angiography for investigation of CAD 
were studied. 81 subjects had 1,2 or 3 vessel disease, 42 subjects were free of CAD and 
used as controls. TAFI antigen levels were analysed in citrated blood samples which 
were taken from the ostium of the left coronary artery. TAFI antigen levels were deter- 
mined with a commercially available sandwich ELISA (Kordia, Leiden, The Netherlands). 
Results: TAFI antigen presented a large range of values, with a 2- to 3-fold increase 
between the 10th and 90th percentiles in patients and controls (mean: 129,3%). CAD 
patients had higher plasma TAFI antigen levels compared to controls. (135,25 % vs 
114.2 %; p=0.01). TAFI antigen levels remained significant between the groups after 
adjustment for cholesterol, triglycedde, gender and smoking (p<0.05). 
Conclusion: These findings suggest that increased TAFI antigen levels determined in 
arterial coronary blood may represent a risk factor for CAD. Because of the large interin- 
dividual variability of TAFI antigen levels in plasma, genetic control may be involved. Fur- 
ther studies are required to evaluate the significance of the observed changes in TAFI 
antigen levels in relation to the development of CAD. 
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1008-71 Arteriogeneais on Demand in Exercising Mice 
Expressing FGF-2 Under the Control of the 
Phoaphoglycerate Klnase Promoter 
Swen Wolfram. Tibor Ziegelhoeffer, Borja Fernandez, J. Douglas Coffin, Shawn Wagner, 
Attain Helisch, Wolfgang Schaper, Max-Planck-lnstitute, Department of Experimental 
Cardiology, Bad Nauheim, Germany. 
Background: Fibroblest growth factor 2 (FGF-2), a potent mitogen for endothelial and 
vascular smooth muscle cell, is implicated in arterial and capillary growth. Exercise is 
beneficial for patients with peripheral arterial obstructive disease (PAOD) considering calf 
blood flow, maximal walking distance, and capillary growth. This study investigated the 
role of regular endurance exercise in a model of PAOD in transganic mice overexpress- 
ing FGF-2. 
Methods: The right femoral arteries of 12 transgenic mice overexprossing FGF-2 and 12 
nontransgenic littermates (FVB/n) mice were occluded. The mice were randomly 
assigned to a sedentary group and a group, which was trained 6 days/week on a mouse 
treadmill. At the end of the exercise program (5 weeks) foot blood flow was determined 
by Laser Doppler Imaging (LDI). Gastrocnemius blood flow was measured using Mag- 
netic Resonance Imaging (MRI). Exercise capacity of all groups was determined by a 
graded exercise test. Postmortem angiograms and histomorphometry of collateral arter- 
ies were performed. 
Results: Only trained FGF-2 transgenic mice demonstrated significantly improved blood 
flow determined by both LDI and MRI when compared to sedentary nontransgenic mice. 
LDI of foot (right/left ratio): 0.97 ± 0.03 vs. 0.66 ± 0.10 
MRI of gastrocnemius (ml/min/g) occluded leg: 0.85 ± 0.06 vs. 0.60 ± 0.06 
MRI of gastrocnemius (ml/min/g) normal leg: 1.16 ± 0.11 vs. 0.83 ± 0.06 
Exercise capacity of trained FGF-2 transgenic animals was dramatically improved (308% 
of sedentary nontransgenic mice). Postmortem angiograms showed the formation of a 
dense collateral network in trained FGF-2 transgenic mice. Histomorphometry of collater- 
als confirmed the angiographic findings of a changed collateral growth pattern in trans- 
genic mice due to exercise. 
Conclusion: Trained FGF-2 transgenic mice demonstrate increased blood flow to the foot 
and to the gastrocnemius, improved exercise capacity, and the formation of a dense col- 
lateral artery network. This study indicates that only sufficient FGF-2 application and 
endurance training lead to improved collateral artery growth. This might be a relevant 
therapeutical approach for humans suffering from PAOD. 
1008-72 Endothelial Progenitor Cell Release in Patients With 
Coronary Artery Disease After Maximal Symptom- 
Limited Exercise Test 
Karsten Lenk. Volker Adams, Dominik Lenz, Atile Tarnok, Sandra Erbs, Gerhard Schuler, 
Rainer Hambrecht, University of Leipzig, Heart Center, Leipzig, Germany. 
Background: Increasing evidence suggests, that endothelial progenitor cells (EPC) play 
an important role in postnatal naovascularization, As animal studies propose ischemia 
seems to be one of the main triggers for the release of EPCs from the bone marrow. Until 
now, however, less is known about the impact of an acute myocardial ischemia on the 
EPC release. Therefore, the aim of this study was to investigate the release of EPCs in 
response to a maximal symptom-limited exercise in patients with symptomatic oronary 
artery disease (CAD). 
Methods: In six patients and six healthy controls blood was taken before and 8, 24 and 
48 hours after a maximal symptom-limited exercise test. Exercise tests were stopped in 
patients due to progressive angina pectoris and/or significant ST segment depression at 
95,8± 10Watt. Mononuclear cells (MNC) were isolated and cultured. After 4 days adher- 
ent EPC were characterized by Di-acLDL uptake and concomitant FITC-lectin binding. 
Double positive cells were counted by Laser Scanning Cytomater (LSC). The endothelial 
origin was further documeted by demonstrating the expression of KDR, vWF and VE- 
cadherin. 
Results: 
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Conclusions: These results demonstrate for the first time that in patients with CAD even 
a very short episode of myocardial ischemia is sufficient o induce a considerable release 
of EPCs. 
1008-73 Ch imer ic  Vascu la r  Endothelial Growth Factor Fusion 
Protein Selectively Inhibits FIk-1 Endothelial Progenitor 
Cells 
Jonathan M, Hill, Marina V. Backer, Joseph M. Backer, Toren Finkel, National Institutes of 
Health, Bethesda, Maryland. 
Endothelial progenitor cells (EPCs) contribute to postnatal vasculogenesis in tumors and 
potentially regulate atherosclerotic plaque size. Selective destruction of EPCs may there- 
fore have therapeutic benefit in certain clinical settings. We have made use of the fact 
that EPCs express high levels of the receptor for vascular endothelial growth factor-2 
(VEGFR-2/FIk-1), An active fusion protein SLT-VEGF/L, containing the catalytic A-sub- 
unit of Shiga-like toxin fused to VEGF121 end a control fusion protein SLT-VEGF/Lci con- 
taining a catalytically inactive mutant of SLT A-subunit (Yl14S and R170L amino acid 
substitutions) fused to VEGF121 were constructed, expressed and purified, EPCs were 
isolated from human peripheral blood mononuclear cells using density gradient centrifu- 
gallon and seeded on fibronectin-ccated plates. An endothelial phenotype of the 
fibronectin-adherant ceils was confirmed by immunohistochemical analysis for Tie-2, 
CD31 and VEGFR-2, and by ability of these cells to uptake Dil-labeled acetylated LDL. A 
dose response curve demonstrated that EPC colony formation was inhibited by SLT- 
VEGF/L with an IC50 of 0.5 nM. This inhibitory effect is -1000-fold more efficacious than 
angiostatin, another reported inhibitor of EPC activity. In contrast, the catalytically inac- 
tive fusion protein SLT-VEGF/Lci did not affect EPC colony formation. Human umbilical 
vein cells (HUVECs) expressing, 2-5 xl04 VEGFR-2/celI, and porcine aortic endothelial 
cells (PAE/KDR) engineered to expressed 2-3x105 VEGFR-2/cell were employed for 
evaluating the effects of SLT-VEGF/L on endothelial cells with different VEGFR-2 density. 
HUVECs were relatively insensitive to SLT-VEGF/L at concentrations up to 20 nM while 
PAE/KDR cells had an IC50 below 1 riM. In summary, a chimeric toxin can inhibit EPC 
activity, cluster and spindle cell formation. This inhibition is a function of high VEGFR-2/ 
FIk-1 expression on these cells. Native endothelisr cells are at least 40-fotd less sensitive 
to the effects of the chimeric toxin. These results suggest the potential clinical applicabil- 
ity of this chimeric toxin for the selective ablation of EPC activity. 
1008-74 Tissue Factor Inhibition Impairs the Maturation of  
Neovascularization in Postnatal Angiogenesis 
Frederic Mououet, Katy Didier, Dalphine Corseaux, AIbin Pourtier, Sylvie Vincent, 
Chantal Vercamer, Bernard Vandenbunder, Chdstophe Bauters, Brigitte Jude, Eric Van 
Belle, Hopital Cardiologique, Lille, France, Institut de Biologie de Lille, France. 
Tissue factor (TF) has an important role in vasculogenesis and tumoral angiogenesis. 
However, its role in post-natal non-tumoral angiogenesis is unknown. We investigated TF 
inhibition effects in a murine model of angiogenesis. Micro-implant loaded with basic 
Fibroblast Growth Factor (bFGF) were grafted in ears of balb/c mice, inducing a local 
angiogenesis. TF was inhibited after systemic injection of an active site-inhibited FVll 
(ASIS, gift from Novo Nordisk). Angiogenic response was accurately quantified by histo- 
logical techniques. Five mice were grafted with control implants. Seventeen were grafted 
with implants loaded with 100 ng bFGF; eight received systemic injection of ASIS (5 ~g/ 
